NCCN clinical practice guidelines In oncology for non-small cell lung cancer. Version 1.2022 (https://www.nccn.org)

Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM et al (2021) Therapy for Stage IV Non-Small-Cell Lung Cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin oncology: official J Am Soc Clin Oncol 39(9):1040–1091

Article  CAS  Google Scholar 

Kelly K, Altorki NK, Eberhardt WE, O’Brien ME, Spigel DR, Crinò L et al (2015) Adjuvant Erlotinib Versus Placebo in patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): a Randomized, Double-Blind, phase III trial. J Clin oncology: official J Am Soc Clin Oncol 33(34):4007–4014

Article  CAS  Google Scholar 

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y et al (2016) First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.The Cochrane database of systematic reviews. (5):Cd010383

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y et al (2020) Overall survival with Osimertinib in untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 382(1):41–50

Article  CAS  PubMed  Google Scholar 

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388

Article  CAS  PubMed  Google Scholar 

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742

Article  CAS  PubMed  Google Scholar 

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222

Article  CAS  PubMed  Google Scholar 

Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L (2018) Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat reviews Clin Oncol 15(11):694–708

Article  CAS  Google Scholar 

Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17(1):38

Article  PubMed  PubMed Central  Google Scholar 

Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y et al (2012) Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg Med Chem Lett 22(19):6301–6305

Article  CAS  PubMed  Google Scholar 

Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L et al (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung cancer (Amsterdam Netherlands) 76(2):177–182

Article  PubMed  Google Scholar 

Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP et al (2017) First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol 28(10):2443–2450

Article  CAS  PubMed  Google Scholar 

Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S et al (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953–961

Article  CAS  PubMed  Google Scholar 

Gu A, Shi C, Xiong L, Chu T, Pei J, Han B (2013) Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin J cancer research = Chung-kuo yen cheng yen chiu 25(1):90–94

Google Scholar 

Shen YW, Zhang XM, Li ST, Lv M, Yang J, Wang F et al (2016) Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. OncoTargets and therapy 9:929–935

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mundle SD, Marathe AS, Chelladurai M (2013) Transient therapy-related surge in serum tumor biomarkers: characterizing behavior and postulating its biologic role. Crit Rev Oncol/Hematol 86(1):15–22

Article  PubMed  Google Scholar 

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D et al (2018) Association of the lung Immune Prognostic Index with Immune checkpoint inhibitor outcomes in patients with Advanced Non-Small Cell Lung Cancer. JAMA Oncol 4(3):351–357

Article  PubMed  PubMed Central  Google Scholar 

Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K et al (2015) Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer 113(2):311–320

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu BB, Xu Y, Lu J, Wu Y, Wang JB, Lin JX et al (2020) Prognostic significance of combined lymphocyte-monocyte ratio and tumor-associated Macrophages in Gastric Cancer Patients after Radical Resection. J Cancer 11(17):5078–5087

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu F, Deng C, Wen Z, Gao Z, Zhao Y, Han H et al (2021) Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Translational lung cancer research 10(7):3144–3154

Article  PubMed  PubMed Central  Google Scholar 

Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M et al (2021) High systemic Immune-Inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg 273(3):532–541

Article  PubMed  Google Scholar 

Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W et al (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin cancer research: official J Am Association Cancer Res 20(23):6212–6222

Article  CAS  Google Scholar 

Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D et al (2019) The systemic-immune-inflammation index independently predicts survival and recurrence in Resectable Pancreatic Cancer and its Prognostic Value depends on bilirubin levels: a retrospective Multicenter Cohort Study. Ann Surg 270(1):139–146

Article  PubMed  Google Scholar 

Li X, Zhang L, Jiang D, Wang Y, Zang A, Ding C et al (2020) Routine-dose and high-dose Icotinib in patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR exon 21-L858R mutation: the Randomized, Phase II, INCREASE Trial. Clin cancer research: official J Am Association Cancer Res 26(13):3162–3171

Article  CAS  Google Scholar 

Shi J, Li D, Liang D, He Y (2021) Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China. Sci Rep 11(1):6817

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garrana SH, Dagogo-Jack I, Cobb R, Kuo AH, Mendoza DP, Zhang EW et al (2021) Clinical and Imaging features of non-small-cell Lung Cancer in Young Patients. Clin Lung Cancer 22(1):23–31

Article  PubMed  Google Scholar 

Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J et al (2014) Metastatic sites and survival in lung cancer. Lung cancer (Amsterdam Netherlands) 86(1):78–84

Article  PubMed  Google Scholar 

Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG (2015) Incidence of brain metastasis at initial presentation of lung cancer. Neurooncology 17(1):122–128

Google Scholar 

Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q et al (2014) Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys 89(2):330–337

Article  PubMed  Google Scholar 

Xue X, Zang X, Liu Y, Lin D, Jiang T, Gao J et al (2020) Independent risk factors for lymph node metastasis in 2623 patients with non-small cell lung cancer. Surg Oncol 34:256–260

Article  PubMed  Google Scholar 

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

Article  CAS  PubMed  Google Scholar 

Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y et al (2020) Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung cancer (Amsterdam Netherlands) 139:1–8

Article  PubMed  Google Scholar 

Onodera T, Goseki N, Kosaki G (1984) [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi 85(9):1001–1005

CAS  PubMed  Google Scholar 

Xue Y, Zhou X, Xue L, Zhou R, Luo J (2019) The role of pretreatment prognostic nutritional index in esophageal cancer: a meta-analysis. J Cell Physiol 234(11):19655–19662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M et al (2020) Prognostic Nutritional Index, Tumor-infiltrating lymphocytes, and prognosis in patients with esophageal Cancer. Ann Surg 271(4):693–700

Article  PubMed  Google Scholar 

Chi J, Xie Q, Jia J, Liu X, Sun J, Chen J et al (2018) Prognostic value of Albumin/Globulin ratio in Survival and Lymph Node Metastasis in patients with Cancer: a systematic review and Meta-analysis. J Cancer 9(13):2341–2348

Article  PubMed  PubMed Central  Google Scholar 

Johannet P, Sawyers A, Qian Y, Kozloff S, Gulati N, Donnelly D et al (2020) Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer.J Immunother Cancer. ; 8(2)

Gao Y, Huo W, Zhang L, Lian J, Tao W, Song C et al (2019) Multiplex measurement of twelve tumor markers using a GMR multi-biomarker immunoassay biosensor. Biosens Bioelectron 123:204–210

Article  CAS  PubMed